{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-038028","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.787586+00:00","generated_at":"2026-06-08T06:18:21.471576+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocugen Q3 net loss $0.06/sh; OCU400 shows 83% stabilization rate; OCU500 selected by NIH","bullets":["Q3 2023 net loss $0.06 per share vs $0.10 year ago; cash $53.5M, down from $90.9M at Dec 2022.","OCU400 Phase 1/2: 83% (10/12) subjects stabilized/improved in BCVA, LLVA, or MLMT; 86% (6/7) RHO subjects improved MLMT.","Completed dosing three LCA patients including pediatric; Phase 3 for RP expected early 2024.","OCU500 (mucosal COVID vaccine) selected by NIH/NIAID Project NextGen for clinical trial inclusion.","OpEx $15.4M in Q3 2023 vs $23.1M in Q3 2022; R&D $6.3M, G&A $9.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-038028","json":"https://secwatch.observer/filing/0001628280-23-038028.json","markdown":"https://secwatch.observer/filing/0001628280-23-038028.md","text":"https://secwatch.observer/filing/0001628280-23-038028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/0001628280-23-038028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/ocgn-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:18:21.471576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8ed75d2099144e9f067f551db95841962110629","claim":"Ocugen, Inc. reported third quarter 2023 results: EPS $0.06 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.06 net loss per common share for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/0001628280-23-038028-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"EPS","value":"$0.06 net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}